PRESENT POSITION
Associate Professor, General Pathology, MED/04
DEPARTMENT OF MEDICO-SURGICAL SCIENCES AND BIOTECHONOLOGIES
EDUCATION AND CAREER
2008 - present: Assistant Professor, General Pathology (SSD MED/04), Dept. of Medico-Surgical Sciences and Siotechonologies, University La Sapienza.
2006 - 2008: Research Associate (Post-doc) - Fellowship of Italian Federation of Cancer Research (FIRC) - Dept. Experimental Medicine, University La Sapienza.
2005 - 2006: Research Associate (Post-doc) - Fellowship of Italian Association of Cancer Research (AIRC) - Dept. Experimental Medicine, University La Sapienza.
2001 - 2004: PhD in Immunological Sciences, Dept of Experimental Medicine, University La Sapienza.
2000: Degree in Biological Sciences, University La Sapienza. Graduation Cum Laude.
MOST RELEVANT RESEARCH LINES
1. Analysis of cellular and molecular mechanisms involved in female solid tumors (breast and ovarian cancers): role of Notch signaling and its implications in molecular mechanisms of drug resistance.
2. Analysis of Notch receptors role in cancer, through both in vitro and in vivo studies:
i) identification of Notch post-transductional modifications (PTMs) events regulating its expression/function in cancers, ii) identification of Notch cross-talk with other signaling pathways in regulating cancer behaviour; iii) identification of therapeutic application of Notch targeting as novel approach in the treatment of Notch-driving cancers.
3. Analysis of cellular and molecular mechanisms involved in T cell leukemia development and progression and identification of new molecular markers of TALLs.
FIVE SELECTED PUBLICATIONS
1. Notch3 contributes to T-cell leukemia growth via regulation of the unfolded protein response.
Maria Valeria Giuli, Giulia Diluvio, Eugenia Giuliani, Giulia Franciosa, Laura Di Magno, Maria Gemma Pignataro, Luca Tottone, Carmine Nicoletti, Zein Mersini Besharat, Giovanna Peruzzi, Maria Pelullo, Rocco Palermo, Gianluca Canettieri, Claudio Talora, Giulia d’Amati, Diana Bellavia, Isabella Screpanti and Saula Checquolo. Oncogenesis. 2020. Oct 18;9(10):93. DOI: 10.1038/s41389-020-00279-7. PMID: 33071287.
2. Notch Signaling Activation as a Hallmark for Triple-Negative Breast Cancer Subtype. Giuli MV, Giuliani E, Screpanti I, Bellavia D, Checquolo S. J Oncol. 2019. Jul 11;2019:8707053. DOI: 10.1155/2019/8707053. eCollection 2019. PMID: 31379945.
3. Kras/ADAM17-dependent Jag1-ICD reverse signaling sustains colorectal cancer progression and chemoresistance. Pelullo M, Nardozza F, Zema S, Quaranta R, Nicoletti C, Besharat ZM, Felli MP, Cerbelli B, d'Amati, G, Palermo R, Capalbo C, Talora C, Marcotullio LD, Giannini G, Checquolo S*, Screpanti I, Bellavia D*. Cancer Research. 2019. Nov 1;79(21):5575-5586. DOI: 10.1158/0008-5472.CAN-19-0145. Epub 2019 Sep 10. PMID: 31506332. * co-corresponding authors
4. NOTCH3 inactivation increases triple negative breast cancer sensitivity to gefitinib by promoting EGFR tyrosine dephosphorylation and its intracellular arrest. G. Diluvio, F. Del Gaudio, M. V. Giuli, G. Franciosa, E. Giuliani, R. Palermo, Z. M. Besharat, M. G. Pignataro, A. Vacca, G. d'Amati, M. Maroder, C. Talora, C. Capalbo, D. Bellavia, S. Checquolo..Oncogenesis. 2018. May 25;7(5):42. DOI: 10.1038/s41389-018-0051-9. PMID: 29795369.
5. Prolyl-isomerase Pin1 controls Notch3 protein expression and regulates T-ALL progression. G. Franciosa, G. Diluvio, F. D. Gaudio, M. V. Giuli, R. Palermo, P. Grazioli, A. F. Campese, C. Talora, D. Bellavia, G. D'Amati, Z. M. Besharat, C. Nicoletti, C. W. Siebel, L. Choy, A. Rustighi, G. D. Sal, I. Screpanti, S. Checquolo.Oncogene. 2016. Sep 8;35(36):4741-51.DOI: 10.1038/onc.2016.5. PMID: 26876201.